26 research outputs found
Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer
No full textPROSPER: A phase 3 study of enzalutamide in nonmetastatic (M0) castration-resistant prostate cancer (CRPC) patients.
No full textEnzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC)
No full textEnzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer.
No full textAnalysis of AR-driven resistance mechanisms in a phase 1/2 study of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.
No full textEnzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC).
No full textEnzalutamide monotherapy : Extended follow-up of a phase II study in hormone-naive prostate cancer patients
No full textTargeting the N‐Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer
No full textDIMDI veröffentlicht amtliche ATC-Klassifikation mit DDD für 2011
No full textAb sofort ist die 8. aktualisierte amtliche Fassung der Anatomisch-Therapeutisch-Chemischen Klassifikation (ATC-Klassfikation) inklusive Definierter Tagesdosen (DDD) erhältlich. Sie ist seit 1. Januar 2011 in Kraft. Das DIMDI bietet die Klassifikation online zum kostenfreien Download an
